NF-κB c-Rel Is a Potential Therapeutic Target for Acute Corneal Transplant Rejection.
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
ppublish
Résumé
The purpose of this study was to determine the role of nuclear factor kappa B (NF-κB) c-Rel during acute corneal transplant rejection and whether targeting c-Rel can reduce corneal transplant rejection. Allogeneic corneal transplantation was performed in wild-type and c-Rel-deficient mice. Corneal graft survival rate, opacity, neovascularization, and edema were evaluated by slit-lamp microscopy. Adeno-associated virus 6 (AAV6) expressing c-Rel-specific small hairpin RNA (AAV6-shRel) and the small-molecule compound pentoxifylline (PTXF) were used to reduce c-Rel expression. Enzyme-linked immunosorbent assay was used to determine the expression of inflammatory cytokines. c-Rel expression was determined by quantitative RT-PCR and western blot. The effect of c-Rel inhibition on corneal transplant rejection was examined using a mouse model of acute allogeneic corneal transplantation. Tear production and corneal sensitivity were measured to determine the potential toxicity of AAV6-shRel and PTXF. The expression of c-Rel and its inflammatory targets was increased in both mice and patients with corneal transplant rejection. Loss of c-Rel reduced corneal transplant rejection in mouse. Both AAV6-shRel and PTXF were able to downregulate the expression of c-Rel and its inflammatory targets in vitro. Treatment with AAV6-shRel or PTXF reduced corneal transplant rejection in mouse and downregulated the expression of inflammatory cytokines in peripheral blood mononuclear cells from patients with corneal transplant rejection. Treatment with AAV6-shRel or PTXF displayed no side effects on tear production or corneal sensitivity. Increased expression of c-Rel is a risk factor for acute corneal transplant rejection, and targeting c-Rel can efficiently reduce corneal transplant rejection.
Identifiants
pubmed: 37962530
pii: 2793011
doi: 10.1167/iovs.64.14.16
pmc: PMC10653260
doi:
Substances chimiques
NF-kappa B
0
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Références
Am J Transplant. 2021 Dec;21(12):3858-3870
pubmed: 34254428
J Exp Med. 2011 Oct 24;208(11):2321-33
pubmed: 22006976
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Immunol Cell Biol. 2017 Aug;95(7):593-600
pubmed: 28202908
Clin Immunol. 2016 Apr;165:47-54
pubmed: 26993753
Curr Opin Ophthalmol. 2013 Jul;24(4):329-35
pubmed: 23680758
Immunol Cell Biol. 2011 Jan;89(1):27-32
pubmed: 20975733
PLoS Pathog. 2011 Jan 20;7(1):e1001259
pubmed: 21283787
Transplantation. 2019 Dec;103(12):2468-2478
pubmed: 31765363
Circ J. 2002 May;66(5):499-504
pubmed: 12030348
Transplantation. 2000 Mar 15;69(5):1008-13
pubmed: 10755569
Arthritis Res Ther. 2008;10(5):R122
pubmed: 18847496
Transpl Immunol. 2021 Feb;64:101353
pubmed: 33238187
Curr Opin Ophthalmol. 2021 Jul 1;32(4):331-337
pubmed: 33989234
J Clin Med. 2020 Apr 28;9(5):
pubmed: 32354200
Immunol Invest. 2014;43(8):888-901
pubmed: 25296240
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):639-46
pubmed: 11867578
Arch Immunol Ther Exp (Warsz). 2021 Nov 6;69(1):32
pubmed: 34741683
Int Immunopharmacol. 2018 Mar;56:9-17
pubmed: 29324391
Ocul Surf. 2005 Oct;3(4 Suppl):S165-8
pubmed: 17216111
Arch Ophthalmol. 1992 Oct;110(10):1392-403
pubmed: 1417537
J Clin Med. 2020 Feb 21;9(2):
pubmed: 32098130
Cell Immunol. 2002 May-Jun;217(1-2):47-57
pubmed: 12426000
J Vis Exp. 2014 Nov 17;(93):e51830
pubmed: 25490741
Neurochem Res. 2012 Apr;37(4):722-31
pubmed: 22219126
Pharmaceutics. 2020 Aug 13;12(8):
pubmed: 32823625
J Ophthalmic Vis Res. 2017 Jan-Mar;12(1):81-92
pubmed: 28299010
Ophthalmology. 1998 Oct;105(10):1855-65
pubmed: 9787355
Br J Ophthalmol. 2002 Sep;86(9):988-92
pubmed: 12185123
J Immunol. 2016 May 15;196(10):3983-91
pubmed: 27183635
Expert Opin Pharmacother. 2012 Apr;13(6):829-40
pubmed: 22424532
J Immunol. 2007 Jan 1;178(1):186-91
pubmed: 17182554
Mol Ther Methods Clin Dev. 2021 Sep 10;23:198-209
pubmed: 34703842
Int J Mol Sci. 2022 Mar 23;23(7):
pubmed: 35408825
Nucleic Acid Ther. 2018 Aug;28(4):209-224
pubmed: 29584585
Invest Ophthalmol Vis Sci. 1984 May;25(5):519-24
pubmed: 6370904
Int Ophthalmol Clin. 2009 Winter;49(1):31-41
pubmed: 19125062
Mol Ther Oncolytics. 2019 Oct 07;15:166-177
pubmed: 31720373
Mol Vis. 2005 Aug 29;11:632-40
pubmed: 16145544
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1740-4
pubmed: 1542667
Immunity. 2009 Dec 18;31(6):932-40
pubmed: 20064450